Side-by-side · Research reference

CardiogenvsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

Cardiogen

Ovagen

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Ovarian tissue chromatin complexes

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

Ovagen

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Theoretical / Russian-tradition

Route

Subcutaneous injection

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

04Side Effects & Safety

Parameter

Cardiogen

Ovagen

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

Unknown — no PubMed-indexed RCTs

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Injection site reaction

—

Possible mild erythema (SQ route)

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

Cardiogen

Ovagen

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Timing

Variable — often evening injection. No established circadian preference.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

—

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

Ovagen

— no documented stacks